Anti-NGF antibodies and methods using same

• US 7,569,364 B2
• Filed: 04/11/2005
• Issued: 08/04/2009
• Est. Priority Date: 12/24/2002
• Status: Active Grant

• Current Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Original Assignee: Pfizer Inc.
• Inventors: Walicke, Patricia A., Rosenthal, Arnon, Shelton, David L.
• Primary Examiner(s): Blanchard; David J.
• Assistant Examiner(s): BRISTOL, LYNN ANNE
• Application Number:
  US11/104,248
• Publication Number:
  US 20080182978A1
• Time in Patent Office: 1,576 Days
• Field of Search: 424/133.1, 424/145.1, 530/388.1, 530/388.24
• US Class Current: 435/70.2
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 29/02 without antiinflammatory effect
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.

Claims

1. A method for treating osteoarthritis pain in an individual comprising administering an effective amount of an anti-NGF antagonist antibody, wherein said antibody comprises a heavy chain variable region comprising:

(a) the CDR1 region shown in SEQ ID NO;

3;

(b) the CDR2 region shown in SEQ ID NO;

4; and

(c) the CDR3 region shown in SEQ ID NO;

5;

and wherein said antibody further comprises a light chain variable region comprising;

(d) the CDR1 region shown in SEQ ID NO;

6;

(e) the CDR2 region shown in SEQ ID NO;

7; and

(f) the CDR3 region shown in SEQ ID NO;

8.

2. The method of claim 1, wherein the antibody is administered at a dosing frequency of once every week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, once every fifteen weeks, once every twenty weeks, once every twenty five weeks, once every twenty six weeks, once every month, once every two months, once every three months, once every four months, once every five months, or once every six months.

3. The method of claim 1, wherein the individual is human.

4. The method of claim 1, wherein the pain is alleviated for a duration of at least about seven days after administration of a single dose of anti-NGF antagonist antibody.

5. The method of claim 1, wherein the pain is alleviated for a duration of at least about fourteen days after administration of a single dose of anti-NGF antagonist antibody.

6. The method of claim 1, wherein the pain is alleviated for a duration of at least about four weeks after administration of a single dose of anti-NGF antagonist antibody.

7. The method of claim 1, wherein the pain is alleviated for a duration of at least about twelve weeks after administration of a single dose of anti-NGF antagonist antibody.

8. The method of claim 1, wherein the anti-NGF antagonist antibody is administered at a dose in a range from 3 μ

g/kg to 300 μ

g/kg.

9. The method of claim 8, wherein the antibody is administered at a dose of 100 μ

g/kg.

10. The method of claim 8, wherein the antibody is administered at a dose of 300 μ

g/kg.

11. The method of claim 1, wherein the anti-NGF antagonist antibody is administered intravenously.

12. The method of claim 1, wherein the anti-NGF antagonist antibody is administered subcutaneously.

13. The method of claim 1, wherein the anti-NGF antagonist antibody is an antibody comprising the amino acid sequence shown in SEQ ID Nos:

1 and 2.

14. The method of claim 1, wherein the anti-NGF antagonist antibody is an antibody comprising the amino acid sequences shown in SEQ ID Nos:

16 and 17.

15. The method of claim 1, wherein the anti-NGF antagonist antibody is a monoclonal antibody.

16. The method of claim 15, wherein the monoclonal antibody is a human antibody, a humanized antibody, a chimeric antibody, or an antibody fragment, such as Fab, Fab′

, F(ab′

)₂, Fv, single chain (ScFv), or a bispecific antibody.